Keros Therapeutics, Inc. $KROS Shares Acquired by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. increased its stake in Keros Therapeutics by 31.1% in the first quarter, accumulating a total of 2,566,321 shares worth approximately $26.15 million.
• Other hedge funds have also made significant adjustments, with some increasing their positions dramatically, indicating strong institutional interest in Keros Therapeutics, which now has 71.56% of its stock owned by institutional investors.
• Equities analysts have varied ratings on Keros, with a consensus rating of "Moderate Buy" and a median target price of $30.00.

Vanguard Group Inc. lifted its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 31.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,566,321 shares of the company's stock after purchasing an additional 609,212 shares during the quarter. Vanguard Group Inc. owned about 6.32% of Keros Therapeutics worth $26,151,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Two Sigma Investments LP grew its holdings in shares of Keros Therapeutics by 226.1% during the 4th quarter. Two Sigma Investments LP now owns 33,664 shares of the company's stock worth $533,000 after purchasing an additional 23,342 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Keros Therapeutics during the 4th quarter worth $730,000. Barclays PLC grew its holdings in shares of Keros Therapeutics by 79.2% during the 4th quarter. Barclays PLC now owns 107,542 shares of the company's stock worth $1,703,000 after purchasing an additional 47,528 shares during the period. TFG Asset Management GP Ltd purchased a new position in shares of Keros Therapeutics during the 4th quarter worth $1,630,000. Finally, Northern Trust Corp grew its holdings in shares of Keros Therapeutics by 11.3% during the 4th quarter. Northern Trust Corp now owns 296,467 shares of the company's stock worth $4,693,000 after purchasing an additional 30,111 shares during the period. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Stock Performance

Shares of KROS traded up $0.15 during midday trading on Wednesday, hitting $15.87. The company had a trading volume of 43,209 shares, compared to its average volume of 953,595. The company's 50-day simple moving average is $14.26 and its 200-day simple moving average is $13.23. The firm has a market capitalization of $644.64 million, a P/E ratio of 51.20, a P/E/G ratio of 1.96 and a beta of 1.06. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.38. The business had revenue of $0.02 million during the quarter, compared to analysts' expectations of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The business's quarterly revenue was up 49002.7% compared to the same quarter last year. During the same quarter last year, the business posted ($1.25) EPS. Equities analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on KROS shares. Wedbush reiterated a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a report on Friday, May 30th. Scotiabank dropped their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research report on Monday, May 12th. Bank of America cut shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $32.00 to $18.00 in a research report on Tuesday, June 10th. Finally, HC Wainwright lowered their price objective on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $30.00.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.